Want To Avoid A Refuse-To-File? Submit ANDA In English, FDA Says
Executive Summary
Generic applications continue to be tripped up by failing to adhere to other well-known standards such as paying user fees, US agency says.
You may also be interested in...
GDUFA II Reviews Start Strong With High First-Cycle Approval Rate
Performance numbers are likely to fluctuate over the course of the program, but the rate of first-cycle approvals during the first month of the new user fee program is more than double the rate during the last year of the old iteration.
FDA Rolls Out Zero-Tolerance Policy On ANDA Typos
In another show of force on generic drug application quality, US agency says it will not accept applications with major deficiencies caused by a typographical error, even if the sponsor corrects it.
ANDA Reviews: First-Cycle Desired, But Two-Cycles OK?
CDER Director Woodcock says it may not be necessary for the ANDA first-cycle approval rate to approach that for NDAs, but lowering the number of cycles to two would be desirable.